MBX MBX Biosciences, Inc. Common Stock
USHealthcareAs of 2026-07-10 16:00
Why MBX matters now
MBX Biosciences, Inc. Common Stock (MBX) is a US stock in Healthcare. The latest InvestLog snapshot shows $61.05 with -7.09% on the session and $2.05B in market capitalization; recent performance reads 1-month +41.59% and YTD +36.43%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-23.5M, and EPS of $-0.50. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -5.5%.
The latest indexable market news headline is "MBX Biosciences: Weekly PTH, Monthly Obesity, Multi-Year Upside (Initiating Buy)" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $70.00; recent insider activity includes Aynechi Tiba filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.58
P/S
0.00
EV/EBITDA
-16.22
DCF Value
$2.02
FCF Yield
-5.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-24.5%
ROA
-19.1%
ROIC
-22.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-23.5M | $-0.50 |
| Q4 2025 | $0.00 | $-22.1M | $-0.49 |
| FY 2025 | $0.00 | $-87.0M | $-2.38 |
| Q3 2025 | $0.00 | $-21.6M | $-0.63 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$68.80
Target (Median)
$70.00
Target Range
$56.00 - $88.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.75
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.